Biomarkers of ovarian function in girls and women with classic galactosemia

Fertility and Sterility

Volumn 92, Issue 1, 2009, Pages 344-351

  Sanders, Rebecca D ^a   Spencer, Jessica B ^b   Epstein, Michael P ^b   Pollak, Susan V ^c   Vardhana, Pratibhasri A ^c   Lustbader, Joyce W ^c   Fridovich Keil, Judith L ^b  

^a Developmental Biology   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

AMH; FSH; FSH bioactivity; Galactosemia; ovarian insufficiency

Indexed keywords

BIOLOGICAL MARKER; FOLLITROPIN; MUELLERIAN INHIBITING FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GALACTOSEMIA; HUMAN; MENARCHE; OVARY FUNCTION; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; GALACTOSEMIAS; HUMANS; INFANT; MIDDLE AGED; OVARY; REFERENCE VALUES; YOUNG ADULT;

EID: 67649236846     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.04.060     Document Type: Article

References (42)

1. Fridovich-Keil J, Walter J. Galactosemia. In: D Valle, et al., eds. Online Metabolic and Molecular Bases of Inherited Disease-OMMBID. New York, McGraw-Hill, chap. 72, updated 2008. www.ommbid.com.
2. Suzuki M.W.C., and Beutler E. Large-scale molecular screening for galactosemia alleles in a pan-ethnic population. Hum Genet 109 (2001) 210-215
3. Welt C. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 68 (2008) 499-509
4. Waggoner D.D., Buist N.R.M., and Donnell G.N. Long-term prognosis in galactosemia: results of a survey of 350 cases. J Inherit Metab Dis 13 (1990) 802-818
5. Guerrero N.V., Singh R.H., Manatunga A., Berry G.T., Steiner R.D., and Elsas L.J. Risk factors for premature ovarian failure in females with galactosemia. J Pediatrics 137 (2000) 833-841
6. Forges T., Monnier-Barbarino P., Leheup B., and Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update 12 (2006) 573-584
7. Bosch A.M., Grootenhuis M.A., Bakker H.D., Heijmans H.S.A., Wijburg F.A., and Last B.F. Living with classical galactosemia: health-related quality of life consequences. Pediatrics 113 (2004) e423-e428
8. Levy H., Driscoll S., Porensky R., and Wender D. Ovarian failure in galactosemia. N Eng J Med 310 (1984) 50
9. Kaufman F.R., Kogut M.D., Donnell G.N., Goebelsmann U., March C., and Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 304 (1981) 994-998
10. Fraser I.S., Russell P., Greco S., and Robertson D.M. Resistant ovary syndrome and premature ovarian failure in young women with galactosaemia. Clin Reprod Fertil 4 (1986) 133-138
11. Twigg S., Wallman L., and McElduff A. The resistant ovary syndrome in a patient with galactosemia: a clue to the natural history of ovarian failure. J Clin Endocrinol Metab 81 (1996) 1329-1331
12. Lai K.W., Cheng L.Y.L., Cheung A.L.M., and O W.S. Inhibitor of apoptosis proteins and ovarian dysfunction in galactosemic rats. Cell Tiss Res 311 (2003) 417-425
13. Bandyopadhyay S., Chakrabarti J., Banerjee S., Pal A.K., Bhattacharyya D., Goswami S.K., et al. Prenatal exposure to high galactose adversely affects initial gonadal pool of germ cells in rats. Hum Reprod 18 (2003) 276-282
14. Chen Y.T., Mattison D.R., Feigenbaum L., Fukui H., and Schulman J.D. Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science 214 (1981) 1145-1147
15. Leslie N.D., Yager K.L., McNamara P.D., and Segal S. A mouse model of galactose-1-phosphate uridyl transferase deficiency. Biochem Mol Med 59 (1996) 7-12
16. Wehrli S., Reynolds R., and Segal S. Evidence for function of UDP galactose pyrophosphorylase in mice with absent galactose-1-phosphate uridyltransferase. Mol Genet Metab 91 (2007) 191-194
17. Haberland C., Perou M., Brunngraber E.G., and Hof H. The neuropathology of galactosemia: a histopathological and biochemical study. J Neuropathol Exp Neurol 30 (1971) 431-447
18. Petry K., Greinix H.T., Nudelman E., Eisen H., Hakomori S., Levy H.L., et al. Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. Biochem Med Metab Biol 46 (1991) 93-104
19. Charlwood J., Clayton P., Keir G., Mian N., and Winchester B. Defective galactosylation of serum transferrin in galactosemia. Glycobiology 8 (1998) 351-357
20. Sturiale L., Barone R., Fiumara A., Perez M., Zaffanello M., Sorge G., et al. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. Glycobiology 15 (2005) 1268-1276
21. Jaeken J., Kint J., and Spaapen L. Serum lysosomal enzyme abnormalities in galactosaemia. Lancet 340 (1992) 1472-1473
22. Prestoz L., Couto A., Shin Y., and Petry K. Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur J Pediatr 156 (1997) 116-120
23. Barrios-De-Tomasi J., Timossi C., Merchant H., Quintanar A., Avalos J.M., Andersen C.Y., et al. Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. Mol Cell Endocrinol 186 (2002) 189-198
24. Menezo Y., Lescaille M., Nicollet B., and Servy E. Pregnancy and delivery after stimulation with rFSH of a galatosemia patient suffering hypergonadotropic hypogonadism: case report. J Assist Reprod Genet 21 (2004) 89-90
25. Visser J., Durlinger A., Peters I., van den Heuvel E., Rose U., Kramer P., et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice. Endocrinology 148 (2007) 2301-2308
26. La Marca A., Stabile G., Carducci Artenisio A., and Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21 (2006) 3103-3107
27. Hehenkamp W.J.K., Looman C.W.N., Themmen A.P.N., de Jong F.H., te Velde E.R., and Broekmans F.J.M. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 91 (2006) 4057-4063
28. Tsepelidis S., Devreker F., Demeestere I., Flahaut A., Gervy C., and Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 22 (2007) 1837-1840
29. Somunkiran A., Yavuz T., Yucel O., and Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 134 (2007) 196-201
30. Wachs D.S., Coffler M.S., Malcom P.J., and Chang R.J. Serum anti-Mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab 92 (2007) 1871-1874
31. Tano M., Minegishi T., Nakamura K., Karino S., and Ibuki Y. Application of Chinese hamster ovary cells transfected with the recombinant human follicle-stimulating hormone (FSH) receptor for measurement of serum FSH. Fertil Steril 64 (1995) 1120-1124
32. Albanese C., Christin-Maitre S., Sluss P.M., Crowley W.F., and Jameson J.L. Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene. Mol Cell Endocrinol 101 (1994) 211-219
33. Gudermann T., Brockmann H., Simoni M., Gromoll J., and Nieschlag E. In vitro bioassay for human serum follicle-stimulating hormone (FSH) based on L cells transfected with recombinant rat FSH receptor: validation of a model system. Endocrinology 135 (1994) 2204-2213
34. Tilly J.L., Aihara T., Nishimori K., Jia X.C., Billig H., Kowalski K.I., et al. Expression of recombinant human follicle-stimulating hormone receptor: species-specific ligand binding, signal transduction, and identification of multiple ovarian messenger ribonucleic acid transcripts. Endocrinology 131 (1992) 799-806
35. La Marca A., Stabile G., Artenisio A.C., and Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21 (2006) 3103-3107
36. Kaufman F.R., Donnell G.N., Roe T.F., and Kogut M.D. Gonadal function in patients with galactosaemia. J Inherit Metab Dis 9 (1986) 140-146
37. Russell P., Bannatyne P., Shearman R.P., Fraser I.S., and Corbett P. Premature hypergonadotropic ovarian failure: clinicopathological study of 19 cases. Int J Gynecol Pathol 1 (1982) 185-201
38. Knauff E., Richardus R., Eijkemans M., Broekmans F., de Jong F., Fauser B., et al. Heterozygosity for the classical galactosemia mutation does not affect ovarian reserve and menopausal age. Reprod Sci 14 (2007) 780-785
39. Cooper G.S., Hulka B.S., Baird D.D., Savitz D.A., Hughes Jr. C.L., Weinberg C.R., et al. Galactose consumption, metabolism, and follicle-stimulating hormone concentrations in women of late reproductive age. Fertil Steril 62 (1994) 1168-1175
40. Liu G., Shi F., Blas-Machado U., Duong Q., Davis V.L., Foster W.G., et al. Ovarian effects of a high lactose diet in the female rat. Reprod Nutr Devel 45 (2005) 185-192
41. Liu G., Shi F., Blas-Machado U., Yu R., Davis V.L., Foster W.G., et al. Dietary galactose inhibits GDF-9 mediated follicular development in the rat ovary. Reprod Toxicol 21 (2006) 26-33
42. Halperin J., Devi S.Y., Elizur S., Stocco C., Shehu A., Rebourcet D., et al. Prolactin signaling through the short form of its receptor represses FOXO3 and its target gene GALT causing a severe ovarian defect. Mol Endocrinol 22 (2008) 513-522